NasdaqGM:LNTHMedical Equipment
Lantheus ASCO Data To Test Radiopharma Pipeline And Valuation Gap Narrative
Lantheus Holdings (NasdaqGM:LNTH) plans to present new clinical data for LNTH-2403, an LRRC15-targeted radiopharmaceutical, at the 2026 ASCO Annual Meeting.
The company will also share real-world data on piflufolastat F 18 imaging use in early-stage prostate cancer at the same conference.
These updates provide fresh detail on both Lantheus's osteosarcoma pipeline and the adoption of its approved prostate cancer imaging agent.
Lantheus focuses on radiopharmaceuticals and imaging agents used...